W
Wuhan Maiwei Metabolic Biotechnology
Metabolomics services for life sciences and health
About Wuhan Maiwei Metabolic Biotechnology
Wuhan Maiwei Metabolic Biotechnology Co., Ltd., also known as Metware, is a biotechnology company specializing in metabolomics technology services and products. Founded in 2015 by Tang Tang, the company has established its headquarters in the Wuhan National Bio-industry Base (Optics Valley Biolake) and has expanded with a North American subsidiary (MetwareBio), an R&D center in Shanghai/Jiaxing, and a diagnostics and production center in Changsha.
The company's business model is centered on providing contract research organization (CRO) services and developing clinical testing products. Its clientele includes universities, scientific research institutes, hospitals, and industrial enterprises across China and internationally. Metware provides a range of services, including widely-targeted metabolomics, non-targeted metabolomics, lipidomics, proteomics, and multi-omics analysis, leveraging a proprietary database of 2.2 million metabolites. The company utilizes over 50 high-performance mass spectrometers to support its services. In the clinical domain, Metware develops diagnostic kits for early cancer screening and prognosis of chronic metabolic diseases. For instance, their colorectal cancer blood test kit showed high sensitivity in detecting advanced adenomas in multi-center trials.
Metware has received significant funding, including a 100 million RMB Series A round in September 2021, led by Sequoia Capital China, and a Series B round in April 2024. The company has been recognized as a National High-Tech Enterprise and a national-level "specialized and innovative little giant" firm in China. Its research collaborations have resulted in publications in prominent academic journals such as Cell, Nature Genetics, and Nature Communications.
Source: Dealroom company dataNews
Open roles
Wuhan Maiwei Metabolic Biotechnology in its local ecosystem
The Wuhan Maiwei Metabolic Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Sequoia- LLLINK Capital LLC
- RIRui Jiang Investment
- TMTianjin Haida Venture Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wuhan Maiwei Metabolic Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wuhan Maiwei Metabolic Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.